Systemic Lupus Erythematosus
Conditions
Keywords
Systemic Lupus Erythematosus
Brief summary
To assess how the absolute bioavailability, dose proportionality, pharmacokinetics, safety and tolerability of epratuzumab compared when given as a subcutaneous (sc) injection as to when given as an intravenous (iv) infusion in Caucasian and Japanese healthy volunteers.
Interventions
BIOLOGICALEpratuzumab sc
Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
BIOLOGICALEpratuzumab iv
Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
Sponsors
Pharmaceutical Research Associates
Richmond Pharmacology Limited
ACM Global Laboratories
Eurofins
The Doctors Laboratory Ltd
UCB Biopharma S.P.R.L.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is male or female. * At the Screening Visit, subject is 18 years to 50 years, inclusive (for Caucasian subjects), or 20 years to 50 years (for Japanese subjects) * Subject must be in good health (physically and mentally) as determined by the investigator on the basis of medical history * Subject has a body weight of 45 kg to 90 kg, inclusive, and body mass index (BMI) between 18.0 kg/m2 and 29.9 kg/m2, inclusive * Japanese subjects are defined as a person carrying a Japanese passport, who is a descendant of 4 Japanese grandparents and has not been outside Japan for more than 5 years prior to screening * Females of childbearing potential are required to have a negative serum pregnancy test at the Screening Visit and must agree to use an acceptable method of birth control during the study and for a period of 3 months after the administration of investigational medicinal product (IMP) * Male subjects must agree to use an acceptable method of contraception during the study and for at least 3 months after receiving IMP unless they have undergone vasectomy
Exclusion criteria
* Subject has donated blood (including through participation in another clinical study) or suffered blood loss (≥450 mL) \<60 days prior to dosing, or has donated platelets \<14 days prior to dosing * Subject has active malignancies or a history of malignancy * Subject has a history of severe or multiple allergies * Subject has a history of chronic infection, recent serious or life-threatening infection * Subject with a recurrent history or active systemic/respiratory infection due to fungal, parasitic, or mycotic pathogens * Subject has a positive HBsAg, anti-HCV or anti-HIV test result during the Screening Period * Subject has a history of or a concurrent clinically significant illness, medical condition, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject upon exposure to epratuzumab or confound the results of the study * Female subjects who are breast feeding, pregnant, or plan to become pregnant during the study or within 3 months following dosing of the IMP * Subjects who are immunocompromised * A confirmed positive urine drug screen * Subject has a history of substance abuse, drug addiction, or alcoholism within 3 years prior to study admission * Subject is unable or unwilling to stop smoking during the inpatient stay * Subject has previous exposure to, or has participated in studies with, any other anti-B-cell therapies * Subject has a medical condition that requires chronic medication * Subject has received a live vaccine in the month prior to the administration of IMP or is scheduled or expected to receive live vaccines during the study period or for 3 months after administration of the IMP
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the plasma concentration time curve from Baseline to time of last detectable concentration (AUC(0-t)) | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
| Area under the plasma concentration time curve from zero up to infinity (AUC(0-inf)) | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
| Maximum observed plasma concentration (Cmax) | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
| Absolute bioavailability of the tested single sc doses | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
Secondary
| Measure | Time frame |
|---|---|
| Time of observed Cmax (tmax) | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
| Apparent terminal half-life (t½) | From Baseline (Day 1 pre-dose) to Day 85 (End of study) |
Countries
United Kingdom
Outcome results
None listed